scholarly journals Homoeopathic treatment leading to a unique response in a patient with renal cell carcinoma

2020 ◽  
Vol 1 (2) ◽  
pp. 19
Author(s):  
Nilanjana Basu

A 45-year-old male patient presented with bilateral solid renal mass probably renal cell carcinoma (RCC). After initial treatment, the patient got symptomatic relief from pain in flanks, acute retention of urine and hematuria. The patient initially declined repeated investigations but agreed for an ultrasound after two years of treatment; the result showed reduction in size of the mass. The urea, creatinine and hemoglobin percentage were normal and reported a normal blood pressure. The quality of life was maintained without the conventional surgery, radiotherapy, chemotherapy, or immunotherapy. While this case provides evidence of positive outcomes for homeopathic therapy, more studies are required in a hospital setting to establish the real extent to which this therapy may be employed.

2010 ◽  
Vol 106 (11) ◽  
pp. 1643-1647 ◽  
Author(s):  
Hideaki Miyake ◽  
Toshifumi Kurahashi ◽  
Kazuki Yamanaka ◽  
Yutaka Kondo ◽  
Atsushi Takenaka ◽  
...  

2006 ◽  
Vol 49 (2) ◽  
pp. 314-323 ◽  
Author(s):  
Wolfgang Dillenburg ◽  
Vassilis Poulakis ◽  
Konstantinos Skriapas ◽  
Rachelle de Vries ◽  
Nikolaos Ferakis ◽  
...  

Cancer ◽  
2021 ◽  
Author(s):  
Ridwan Alam ◽  
Hiten D. Patel ◽  
Zhuo T. Su ◽  
Joseph G. Cheaib ◽  
Yasser Ged ◽  
...  

Author(s):  
Thomas E. Hutson ◽  
Gregory R. Thoreson ◽  
Robert A. Figlin ◽  
Brian I. Rini

The treatment landscape for renal cell carcinoma (RCC) is a dynamic process that has seen considerable change in recent years. We have seen a rebirth of original breakthroughs with immune checkpoint inhibitors showing promise in patients with treatment-refractory disease. The optimal sequencing of treatments and incorporation of novel therapeutics are actively being investigated and have yet to be determined. The clinical challenges of this evolving treatment paradigm can be attributed to cost considerations, toxicity, and defining endpoints in the management of advanced RCC. As novel therapeutics emerge, finding the optimal treatment regimen for patients will have an increasing focus on patient-centered outcomes and improvement in quality of life in addition to improving survival.


2009 ◽  
Vol 1 ◽  
pp. CMT.S2037 ◽  
Author(s):  
Anthony Jarkowski ◽  
Michael K.K. Wong

Interleukin-2 (IL-2) can provide long term durable remissions for patients with advanced or metastatic renal cell carcinoma. The perceived morbidity and the difficulties in delivering this treatment hampered its widespread use in these patients. This review aims to place IL-2 in the modern milieu by reviewing the pharmacology, efficacy and toxicity of this drug. These will be contrasted and compared with the new targeted-agents. The methodology of providing high dose IL-2 treatment, follow-up care and its impact on patient quality of life will be discussed. Importantly, the ability of these agents to provide durable, complete remissions for RCC patients will be placed in context. The goal is to provide the perspective and framework for the reader to balance the important attributes of each of these drugs during the clinical decision making process.


Sign in / Sign up

Export Citation Format

Share Document